Advances in hemophilia: experimental aspects and therapy.
This article describes recent clinical and research advances in hemophilia therapy. Different prophylactic regimens for the management of severe hemophilia are described along with the use of adjuvant treatment options to achieve hemostasis. The safety and efficacy of radionuclide synovectomy with phosphorus 32-sulfur colloid to treat existing joint arthropathy also are described. The development of inhibitors to factor VIII or IX remains a challenge for hemophilia care and recent approaches to achieve immune tolerance induction are discussed. Finally, recent advances in hemophilia are mentioned, including the role of iron, inflammation, and angiogenesis in the pathogenesis of hemophilic arthopathy.
Rodriguez
Nidra I
NI
Division of Pediatrics, Hematology Section, The University of Texas Health Science Center, 6411 Fannin, Houston, TX 77030, USA. nidra.i.rodriguez@uth.tmc.edu
Hoots
W Keith
WK
D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D002353:Carrier State; D002648:Child; D005820:Genetic Testing; D015316:Genetic Therapy / Q000639:trends; D006395:Hemarthrosis / Q000209:etiology / Q000628:therapy; D006467:Hemophilia A / Q000150:complications / Q000235:genetics / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D010375:Pedigree
D000933:Antifibrinolytic Agents